Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Phase 2
Completed
- Conditions
- Covid19Corona Virus Infection
- Interventions
- Diagnostic Test: Biochemistry blood testDiagnostic Test: Hematology blood testDiagnostic Test: D-Dimer test (coagulation)Diagnostic Test: Inflammatory markersDiagnostic Test: Vital signsDiagnostic Test: VAS scaleDiagnostic Test: WHO Ordinal ScoreDiagnostic Test: COVID-19-Related Symptoms assessmentDiagnostic Test: COVID-19-Impact on Quality-of-Life QuestionnaireDiagnostic Test: Pregnancy testDiagnostic Test: Physical examinationDiagnostic Test: PK parametersDiagnostic Test: SARS-CoV-2 test (PCR)Diagnostic Test: ECGDrug: Treatment administration (twice a day)
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 240
- Registration Number
- NCT05037162
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Phase 3
- Conditions
- Corona Virus InfectionCovid19SARS-CoV Infection
- Interventions
- Diagnostic Test: Confirm SARS-CoV-2 infectionDrug: Placebo administrationProcedure: Physical ExaminationProcedure: Vital SignsDiagnostic Test: Hematology blood testDiagnostic Test: Biochemistry blood testOther: NEWS scoreDiagnostic Test: PK testDiagnostic Test: blood test for inflammatory markersDiagnostic Test: D-dimer testOther: VAS scaleDiagnostic Test: Urine pregnancy test for women of childbearing potentialProcedure: ECGOther: COVID-19-Impact on Quality of Life Questionnaire
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 252
- Registration Number
- NCT04802382
- Locations
- 🇮🇱
Nazareth Hospital EMMS, Nazareth, North, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies
Phase 2
Withdrawn
- Conditions
- Children EpilepsyChildren and Adolescents With Resistant EpilepsiesResistant Epilepsy, DrugAdolescent Epilepsy
- Interventions
- Drug: PlaceboDiagnostic Test: ECGDiagnostic Test: EEGDiagnostic Test: Blood and urine collection
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Registration Number
- NCT04406948
- Locations
- 🇮🇱
Schneider Children's Medical Center of Israel, Petach Tikvah, Central District, Israel
🇸🇮University Children's Hospital Ljubljana University Medical Centre Ljubljana, Ljubljana, Slovenia
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Phase 2
Completed
- Conditions
- Corona Virus InfectionSARS-CoV 2COVID-19Coronavirus InfectionCoronavirus
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- MGC Pharmaceuticals d.o.o
- Target Recruit Count
- 50
- Registration Number
- NCT04382040
- Locations
- 🇮🇳
Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India
🇮🇱Hillel Yaffe Medical Center, Hadera, Haifa, Israel
🇮🇱Nazareth Hospital EMMS, Nazareth, North, Israel
© Copyright 2025. All Rights Reserved by MedPath